Cerebrospinal fluid high-mobility group box protein 1 in neuromyelitis optica and multiple sclerosis

NeuroImmunoModulation

Volumn 20, Issue 2, 2013, Pages 113-118

  Wang, Honghao ^a,b   Wang, Kai ^a   Wang, Conghui ^a   Xu, Fangcheng ^a   Zhong, Xiaonan ^b   Qiu, Wei ^b   Hu, Xueqiang ^b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

High mobility group box protein 1; Interleukin 17; Interleukin 6; Multiple sclerosis; Neuromyelitis optica

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 17; INTERLEUKIN 6;

ADOLESCENT; ADULT; ARTICLE; CEREBROSPINAL FLUID; CHILD; CLINICAL ARTICLE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HMGB1 PROTEIN; HUMANS; INTERLEUKIN-17; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; YOUNG ADULT;

EID: 84872269578     PISSN: 10217401     EISSN: 14230216     Source Type: Journal    
DOI: 10.1159/000345994     Document Type: Article

References (33)

1. Lassmann H: Multiple sclerosis pathology: evolution of pathogenetic concepts. Brain Pathol 2005; 15: 217-222.
2. Cosentino M, Zaffaroni M, Trojano M, Giorelli M, Pica C, Rasini E, Bombelli R, Ferrari M, Ghezzi A, Comi G, Livrea P, Lecchini S, Marino F: Dopaminergic modulation of CD4+CD25(high) regulatory T lymphocytes in multiple sclerosis patients during interferon therapy. Neuroimmunomodulation 2012; 19: 283-292.
3. Kira J: Neuromyelitis optica and Asian phenotype of multiple sclerosis. Ann NY Acad Sci 2008; 1142: 58-71.
4. Erlandsson Harris H, Andersson U: Minireview: the nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol 2004; 34: 1503-1512.
5. Yamada S, Maruyama I: HMGB1, a novel inflammatory cytokine. Clin Chim Acta 2007; 375: 36-42.
6. Naglova H, Bucova M: HMGB1 and its physiological and pathological roles. Bratisl Lek Listy 2012; 113: 163-171.
7. de Souza AW, Westra J, Limburg PC, Bijl M, Kallenberg CG: HMGB1 in vascular diseases: its role in vascular inflammation and atherosclerosis. Autoimmun Rev 2012; 11: 909-917.
8. Andersson U, Tracey KJ: HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011; 29: 139-162.
9. Messmer D, Yang H, Telusma G, Knoll F, Li J, Messmer B, Tracey KJ, Chiorazzi N: High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 2004; 173: 307-313.
10. Shimazaki J, Matsumoto N, Ogura H, Muroya T, Kuwagata Y, Nakagawa J, Yamakawa K, Hosotsubo H, Imamura Y, Shimazu T: Systemic involvement of high-mobility group box 1 protein and therapeutic effect of anti-highmobility group box 1 protein antibody in a rat model of crush injury. Shock 2012; 37: 634-638.
11. Nogueira-Machado JA, Volpe CM, Veloso CA, Chaves MM: HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation. Expert Opin Ther Targets 2011; 15: 1023-1035.
12. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, Abraham E: Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004; 279: 7370-7377.
13. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Naworth P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Kiener PA, Coyle AJ: Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007; 8: 487-496.
14. Hou CH, Fong YC, Tang CH: HMGB-1 induces IL-6 production in human synovial fibroblasts through c-Src, Akt and NF-B pathways. J Cell Physiol 2011; 226: 2006-2015.
15. Penzo M, Molteni R, Suda T, Samaniego S, Raucci A, Habiel DM, Miller F, Jiang HP, Li J, Pardi R, Palumbo R, Olivotto E, Kew RR, Bianchi ME, Marcu KB: Inhibitor of NFkappa B kinases alpha and beta are both essential for high mobility group box 1-mediated chemotaxis. J Immunol 2010; 184: 4497-4509.
16. Sundberg E, Fasth AE, Palmblad K, Harris HE, Andersson U: High mobility group box chromosomal protein 1 acts as a proliferation signal for activated T lymphocytes. Immunobiology 2009; 214: 303-309.
17. Shi Y, Sandoghchian Shotorbani S, Su Z, Liu Y, Tong J, Zheng D, Chen J, Liu Y, Xu Y, Jiao Z, Wang S, Lu L, Huang X, Xu H: Enhanced HMGB1 expression may contribute to Th17 cells activation in rheumatoid arthritis. Clin Dev Immunol 2012; 2012: 295081.
18. Wang H, Zhong X, Wang K, Qiu W, Li J, Dai Y, Hu X: Interleukin 17 gene polymorphism is associated with anti-aquaporin 4 antibody-positive neuromyelitis optica in the Southern Han Chinese-a case control study. J Neurol Sci 2012; 314: 26-28.
19. Wang H, Dai Y, Qiu W, Lu Z, Peng F, Wang Y, Bao J, Li Y, Hu X: Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J Clin Neurosci 2011; 18: 1313-1317.
20. Li Y, Wang H, Long Y, Lu Z, Hu X: Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis. J Neuroimmunol 2011; 234: 155-160.
21. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG: Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489.
22. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS: Diagnostic criteria for multiple sclerosis: 2010 revisions to the Mc-Donald criteria. Ann Neurol 2011; 69: 292-302.
23. Wang H, Wang K, Zhong X, Dai Y, Qiu W, Wu A, Hu X: Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica. Neuroimmunomodulation 2012; 19: 304-308.
24. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ: HMGB-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-251.
25. Gao HM, Zhou H, Zhang F, Wilson BC, Kam W, Hong JS: HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J Neurosci 2011; 31: 1081-1092.
26. Youssef RE, Ledingham MA, Bollapragada SS, O'Gorman N, Jordan F, Young A, Norman JE: The role of Toll-like receptors (TLR-2 and-4) and triggering receptor expressed on myeloid cells 1 (TREM-1) in human term and preterm labor. Reprod Sci 2009; 16: 843-856.
27. Fischer MT, Sharma R, Lim JL, Haider L, Frischer JM, Drexhage J, Mahad D, Bradl M, van Horssen J, Lassmann H: NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain 2012; 135: 886-899.
28. Andersson A, Covacu R, Sunnemark D, Danilov AI, Dal Bianco A, Khademi M, Wallström E, Lobell A, Brundin L, Lassmann H, Harris RA: Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J Leukoc Biol 2008; 84: 1248-1255.
29. Kimura A, Kishimoto T: IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010; 40: 1830-1835.
30. Uzawa A, Mori M, Sato Y, Masuda S, Kuwabara S: CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse. J Neurol Neurosurg Psychiatry 2012; 83: 339-340.
31. Uzawa A, Mori M, Ito M, Uchida T, Hayakawa S, Masuda S, Kuwabara S: Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol 2009; 256: 2082-2084.
32. Su Z, Sun C, Zhou C, Liu Y, Zhu H, Sandoghchian S, Zheng D, Peng T, Zhang Y, Jiao Z, Wang S, Xu H: HMGB1 blockade attenuates experimental autoimmune myocarditis and suppresses Th17-cell expansion. Eur J Immunol 2011; 41: 3586-3595.
33. Zhang Y, Yao YM, Huang LF, Dong N, Yu Y, Sheng ZY: The potential effect and mechanism of high-mobility group box 1 protein on regulatory T cell-mediated immunosuppression. J Interferon Cytokine Res 2011; 31: 249-257.